(Q43246075)

English

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

scientific article published on 6 November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Leo A Niemeier

1

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

David J Dabbs

2

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Sushil Beriwal

3

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Joan M Striebel

4

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Rohit Bhargava

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

publication date

6 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Modern Pathology

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

205-212

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

https://scigraph.springernature.com/pub.10.1038/modpathol.2009.159

0 references

The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Trastuzumab-associated cardiotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Therapeutic strategies for triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

A new hormonal therapy for estrogen receptor-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Histopathologic variables predict Oncotype DX recurrence score

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Minireview: nuclear receptors and breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Androgen receptors as a prognostic and predictive factor in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Identification of molecular apocrine breast tumours by microarray analysis.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Androgen receptors are frequently expressed in mammary and extramammary Paget's disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Androgen Receptor Expression in Estrogen Receptor-Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

21 January 2018

Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgens and androgen receptors: a clinically neglected sector in breast cancer biology

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

7 January 2021

based on heuristic

inferred from DOI database lookup

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.159

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MODPATHOL.2009.159

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43246075&oldid=1984824772"